Galit Zuckerman-Stark

Founder & CEO of Medasense Biometrics Ltd. Medasense is a medical device company that has developed a non-invasive platform technology enabling objective assessment of pain response. Better assessment of pain can contribute to improved clinical outcomes and a reduction in costs associated with non-optimal pain management. Medasense was founded upon discovering that while advanced algorithms are used frequently in many different industries like semiconductors, communication, etc., the discipline of medicine and specifically pain is still left behind. At present, pain is still assessed through a patients subjective self-reporting or a review of a patient’s vital signs by clinicians where they are unable to communicate (under sedation, mentally ill, etc.). Today Medasense is selling in Europe, Canada, LATM, Australia, Israel, with key strategic partners such as Medtronic that sells Medasense products in key territories in western Europe. Medasense flagship product PMD200 with its NOL® - Nociception level Index, has been repeatedly referred to in peer reviewed journals and by opinion leaders as the most robust, state-of-the-art and reliable solution to measure intra-operative pain (nociception). Clinical Studies published showed improved outcomes connected to reduced costs and the NOL® was included in Critical Care Guidelines To learn more about the Medasense commercial opportunity and technology, please message me and I’ll get back to you as soon as possible. Many thanks, Galit www.medasense.com